Balázs Sándor

Dr. Balázs Sándor

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2012 in Journal of Molecular Neuroscience
Verified
Journal Article
Closed access
PDF file
DRDora Reglodi
Dora Reglodi
PKP. Kiss
P. Kiss
KSK. Szabadfi
K. Szabadfi
TATamas Atlasz
Tamas Atlasz
RGR. Gabriel
R. Gabriel
ATA. Tamas
A. Tamas

12 August 2014 in Journal of Molecular Neuroscience
Verified
Journal Article
Closed access
PDF file
BSBalázs Sándor
Balázs Sándor
KFK. Fintor
K. Fintor
SFSz. Felszeghy
Sz. Felszeghy
TJT. Juhasz
T. Juhasz
DRD. Reglodi
D. Reglodi
Andrea TamasAndrea Tamas
Andrea Tamas

6 February 2017 in Journal of Molecular Neuroscience
Verified
Journal Article
Closed access
PDF file
JFJozsef Farkas
Jozsef Farkas
BSBalázs Sándor
Balázs Sándor
ATAndrea Tamas
Andrea Tamas
PKPeter Kiss
Peter Kiss
HHHitoshi Hashimoto
Hitoshi Hashimoto
DRDora Reglodi
Dora Reglodi

10 August 2018 in Journal of Molecular Neuroscience
Verified
Journal Article
Closed access
PDF file
BFB. D. Fulop
B. D. Fulop
BSBalázs Sándor
Balázs Sándor
ESE. Szentleleky
E. Szentleleky
EKE. Karanyicz
E. Karanyicz
DRD. Reglodi
D. Reglodi
Andrea TamasAndrea Tamas
Andrea Tamas

6 May 2016 in Journal of Molecular Neuroscience
Verified
Journal Article
Closed access
PDF file
BSBalázs Sándor
Balázs Sándor
KFK. Fintor
K. Fintor
DRD. Reglodi
D. Reglodi
DFD. B. Fulop
D. B. Fulop
ZHZ. Helyes
Z. Helyes
Andrea TamasAndrea Tamas
Andrea Tamas

1 April 2012 in Technology in Cancer Research & Treatment
Verified
Journal Article
Open access
ISI. Szanto
I. Szanto
LML. Mark
L. Mark
ABA. Bona
A. Bona
GMG. Maasz
G. Maasz
BSBalázs Sándor
Balázs Sándor
Ferenc GallyasFerenc Gallyas
Ferenc Gallyas
The success of tumour therapy depends considerably on early diagnosis. Therefore, we aimed to develop a widely available, cheap, non-invasive, high-throughput method suitable for screening high-risk populations, at least, for early signs of malignant transformation in the oral cavity. First, in order to identify suitable tumour marker candidates, we compared the protein patterns of five selected saliva samples obtained from healthy controls and tumour patients after electrophoretic separation, excised the bands that were consistently up-regulated in the tumour patients only, and performed matrix-assisted laser-desorption ionisation (MALDI)-time of flight (TOF) tandem mass spectrometry (MS/MS) analysis of the proteins in these bands after in-gel tryptic digestion. From the panel of proteins identified, we chose annexin 1 and peroxiredoxin 2 for further studies based on their presence in the saliva of all five oral cancer patients only. Then, we performed a homology search of protein databases using the primary sequence of each in silico tryptic fragment peptide of these two proteins as bait, and selected a unique peptide for each. Finally, we performed targeted MALDI-TOF MS peptide analysis in a blinded fashion on all samples obtained from 20 healthy controls and 22 tumour patients for the presence of these peptides. We found both peptides present in the saliva samples of all cancer patients only. Even though these tumour markers should be validated in a wider population, our results indicate that targeted MALDI-TOF MS analysis of unique peptides of putative saliva protein tumour biomarkers could be the method of choice for cost-efficient, high-throughput screening for the early detection of oral cancer.